The Sagility block deal is the stake sale to watch on Friday, October 30. Promoter Sagility B.V., the Netherlands-based parent, is set to sell about 12% of the healthcare services company through a block deal worth roughly ₹2,377 crore, with a floor price of ₹42.45 a share, CNBC-TV18 reported on Thursday night, citing deal details.
That floor is a discount of up to 4.9% to Thursday’s NSE close of ₹44.66. The stock had already slipped 1.4% in that session. Moneycontrol, citing sources, said IIFL Capital is running the deal, sized at up to $249.6 million, and put the discount at 4.94% to the October 29 close.
In this article
Sagility block deal: the key terms
- Seller: promoter Sagility B.V.
- Size: about 12% of the company’s total equity, roughly ₹2,377 crore.
- Floor price: ₹42.45 per share.
- Lock-up: 365 days on the promoter’s remaining holding after the sale.
According to ET Markets, September-quarter shareholding data showed Sagility B.V. holding 2,38,51,29,151 shares, or 50.95% of the company. On BSE the stock closed at ₹44.69 on Thursday, down 1.17% from ₹45.22. If the full 12% changes hands, simple subtraction puts the promoter at roughly 39%.
Not the first sell-down
The promoter has been trimming steadily. Livemint noted that Sagility B.V. held 67.38% a year earlier. Moneycontrol said it sold a 16.43% stake through a bulk deal in November 2025, which took its holding down to 50.95%. CNBC-TV18, citing Trendlyne data, put that sale at 76.9 crore shares at an average of ₹47.60 on the NSE on November 14, 2025.
The timing isn’t great for sellers. The stock is down more than 14% so far in 2026, though Livemint pointed out it has bounced about 24% from its yearly low of ₹35.83. A fresh block of supply at a discount can weigh on the price on deal day. How much depends on who turns up on the buy side.
What the latest quarter showed
The deal lands right after Sagility’s Q2 FY27 numbers. ET Markets reported:
- Revenue of ₹2,032.1 crore, up 22.5% year-on-year; constant-currency growth was 12.2%.
- Adjusted profit after tax of ₹325.4 crore, up 8.1% year-on-year.
- Adjusted EBITDA of ₹535.3 crore, up 23%, with the adjusted EBITDA margin at 26.3% of revenue.
- An interim dividend of ₹0.15 per share and a total active client group base of 105.
The company also bought Chirok Health LLC to grow its provider business. So the business is still growing at a decent clip. Profit, on an adjusted basis, is growing far slower than revenue, and that gap is something we’d keep an eye on. If you want a framework for reading numbers like these, our guide on how to analyse quarterly results of a company walks through it.
What it means for shareholders
A promoter sale doesn’t by itself tell you why the seller wants out, but it does add supply. Watch three things on Friday: the final price versus the ₹42.45 floor, the names of the buyers once exchange block deal data comes out, and whether the stock holds up after the deal clears. The 365-day lock-up does take away the near-term worry of another promoter sale soon. For the wider market mood going into the session, see how the Sensex closed on October 29.
Disclaimer: This article is for information and education only and is not investment advice. Please do your own research or consult a SEBI-registered adviser before making any investment decision.
Leave a Reply
Join the conversation
Commenting is open to registered readers. Sign up with just your email — no password needed, and it takes under a minute.
Sign up to comment Log in